- $20.67m
- -$3.74m
- 14
- 38
- 22
- 13
Annual income statement for BioVie, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2.69 | 138 | 27.3 | 45.1 | 32.2 |
| Operating Profit | -2.69 | -138 | -27.3 | -45.1 | -32.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -16.7 | -130 | -26.1 | -50.3 | -32.1 |
| Net Income After Taxes | -16.7 | -130 | -26.1 | -50.3 | -32.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -16.7 | -130 | -26.1 | -50.3 | -32.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -33.8 | -184 | -26.1 | -50.3 | -33 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -68.5 | -148 | -10.6 | -15.5 | -7.31 |